The invention relates to a method of customizing a nail-biting and/or finger sucking treatment solution, and a kit for providing a nail-biting and finger sucking treatment that is customizable for a wide range of afflicted users seeking to break a persistent nail-biting and/or finger sucking habit. In exemplary embodiments, the composition kit includes two separate containers, a first container having a nail growth-promoting, waterproofing composition that may be applied directly on a user's nails; and a second container may include an additive for customizing a bitterness factor of the first composition. Typically, the first container includes an applicator such as a brush. To facilitate adding the additive in a manner that is easily customizable, the second container may include a dropper for adding small doses of the additive composition to the first composition. The customizable kit allows the user to safely adjust the bitterness so that the treatment remains effective.

The invention relates to a method of customizing a nail-biting and/or finger sucking treatment solution, and a kit for providing a nail-biting and finger sucking treatment that is customizable for a wide range of afflicted users seeking to break a persistent nail-biting and/or finger sucking habit. In exemplary embodiments, the composition kit includes two separate containers, a first container having a nail growth-promoting, waterproofing composition that may be applied directly on a user's nails; and a second container may include an additive for customizing a bitterness factor of the first composition. Typically, the first container includes an applicator such as a brush. To facilitate adding the additive in a manner that is easily customizable, the second container may include a dropper for adding small doses of the additive composition to the first composition. The customizable kit allows the user to safely adjust the bitterness so that the treatment remains effective.

A new pharmaceutical composition consisting of an oral aqueous suspension for the prevention and treatment of gastric ulcers and colon cancer is disclosed, as well as the procedure for preparing it. This suspension is characterized by containing a purified extract with fatty alcohols from beeswax, microcrystalline cellulose and excipients accepted by the pharmaceutical industry. The method of preparing this suspension is characterized in that the fatty alcohol extract is subjected to a process of particle size reduction to <1.5 micrometers in the presence of an emulsifying agent at >1000 rpm; the mixture of said active ingredient with microcrystalline cellulose in the proportion and concentration in which they are formulated, makes these components act synergistically, conferring powerful antiulcer and chemoprotective effects to this composition.

A new pharmaceutical composition consisting of an oral aqueous suspension for the prevention and treatment of gastric ulcers and colon cancer is disclosed, as well as the procedure for preparing it. This suspension is characterized by containing a purified extract with fatty alcohols from beeswax, microcrystalline cellulose and excipients accepted by the pharmaceutical industry. The method of preparing this suspension is characterized in that the fatty alcohol extract is subjected to a process of particle size reduction to <1.5 micrometers in the presence of an emulsifying agent at >1000 rpm; the mixture of said active ingredient with microcrystalline cellulose in the proportion and concentration in which they are formulated, makes these components act synergistically, conferring powerful antiulcer and chemoprotective effects to this composition.

The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. ##STR00001## wherein A is —(CH2).sub.a-CH═CH—(CH 2).sub.5-a-H where a is from 0 to 5, —(CH2).sub.b-CH═CH—(CH 2).sub.6-b-H where b is from 0 to 6, —(CH2).sub.c-CH═CH—(CH 2).sub.7-c-H where c is from 0 to 7, —(CH2).sub.d-CH═CH—(CH 2).sub.8-d-H where d is from 0 to 8, or —CH2).sub.e-CH═CH—(CH 2).sub.9-d-H where d is from 0 to 9;
B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. ##STR00001## wherein A is —(CH2).sub.a-CH═CH—(CH 2).sub.5-a-H where a is from 0 to 5, —(CH2).sub.b-CH═CH—(CH 2).sub.6-b-H where b is from 0 to 6, —(CH2).sub.c-CH═CH—(CH 2).sub.7-c-H where c is from 0 to 7, —(CH2).sub.d-CH═CH—(CH 2).sub.8-d-H where d is from 0 to 8, or —CH2).sub.e-CH═CH—(CH 2).sub.9-d-H where d is from 0 to 9;
B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

The invention relates to the use of herbal preparation, characterized by presence of 4 dominant compounds (carvacrol from about 35% to about 50%, y-terpinene from about 10% to about 30%, thymol from about 10% to about 25%, p-cymene from about 8% to about 20%, as expressed in % of total peak area in GC/MS chromatogram), obtained by mixing at least two essential oils from species selected from the group of genera Satureja L., Origanum L. and Thymus L., to prepare food supplement or medicament for treatment and prevention of gastric Helicobacter pylori infection in humans The mixture may be placed on liquid or solid carrier and capsulated in non gastro-resistant capsules. The invention also relates to dosage regiment of herbal preparation for treatment and prevention of patients with Helicobacter pylori infection which leads to successful eradication of bacteria without any side-effects.